• In late March 2026, AbbVie detailed extensive new clinical and real-world dermatology data for Skyrizi and Rinvoq at the American Academy of Dermatology meeting, while also facing investor scrutiny over a shareholder proposal to require an independent board chair.
• At the same time, market concern about potential US tariffs on imported branded and patented drugs has raised fresh questions about AbbVie’s exposure to shifting drug-pricing and trade policies.
• Next, we’ll examine how heightened tariff risk on imported branded drugs may influence AbbVie’s immunology-focused investment narrative and longer-term outlook.

Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

AbbVie Investment Narrative Recap

To own AbbVie, you have to believe its immunology and neuroscience engines, led by drugs like Skyrizi and Rinvoq, can support earnings despite patent cycles, pricing pressure and higher debt. The key near term catalyst remains execution in immunology, while the biggest emerging risk is policy driven, with potential US tariffs on imported branded drugs adding another layer of uncertainty to existing drug pricing and reimbursement pressures. So far, the tariff headlines look more sentiment driven than fundamentally specific to AbbVie.

The most relevant recent update is AbbVie’s extensive new dermatology data for Skyrizi and Rinvoq at the AAD 2026 meeting, which reinforced long term safety, disease control and quality of life outcomes across psoriasis and atopic dermatitis. For investors focused on AbbVie’s immunology narrative, this kind of real world and late stage evidence helps support confidence in the durability of the franchise at a time when both competition and policy risk are firmly in the spotlight.

Yet for investors, the tariff and broader drug pricing risk is something you really need to understand before you...

AbbVie's narrative projects $77.7 billion revenue and $22.8 billion earnings by 2029. This requires 8.3% yearly revenue growth and a $18.6 billion earnings increase from $4.2 billion today.

Uncover how AbbVie's forecasts yield a $249.14 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community range from about US$249 to US$369, underlining how differently you and other investors can view AbbVie. Against that spread, the risk of tighter government drug price controls and potential tariffs on imported branded medicines could be an important factor shaping how resilient AbbVie’s future earnings profile really looks.

Explore 4 other fair value estimates on AbbVie - why the stock might be worth as much as 77% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AbbVie research is our analysis highlighting 2 key rewards and 5 important warning signs that could impact your investment decision.
• Our free AbbVie research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbbVie's overall financial health at a glance.

No Opportunity In AbbVie?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.